GLYC

Rivipansel (GMI-1070)

SCD - Acute Vaso-Occlusive Crisis (VOC)

Stage (next event)

Expected Date

Phase 3

December 7, 2020

Catalyst Info & Data Links

TITLE: Rivipansel (GMI-1070) for SCD - Acute Vaso-Occlusive Crisis (VOC)  - Phase 3

  • ClinicalTrial.gov (NCT02187003): Efficacy and Safety of Rivipansel (GMI-1070) in the Treatment of Vaso-Occlusive Crisis in Hospitalized Subjects With Sickle Cell Disease


WHAT IS THE NEXT CATALYST EVENT?

  • FDA Guidance on Next Steps  

  • ASH Detailed meeting 


WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?

  • December 7th, 2020 (ASH Meeting)


PRIOR DATA

PRESS RELEASES

Mechanism of Action

MECHANISM OF ACTION

  • Rivipansel, a glycomimetic drug candidate that binds to all three members of the selectin family (E-, P- and L-selectin). Rivipansel is a pan-selectin inhibitor, a molecule that blocks the activity of cell adhesion molecules called selectins in the blood vessels. (Source:SickleCellAnemiaNews)

Updated by JM 

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

Recent Posts

See what the community is saying - click to see full post

AMRN - Near-Term Price Acton Depends on Breadth of Label, but Acquisition Chatter and Quarterly Resu

Lots of Uncertainty in Upcoming GLYC Sickle Cell Readout

AMP Trades Last Week

Anthera Pharmaceuticals: A Series Of Unfortunate Events

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon